Article

625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications

2024-09-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 06bc2017-bdfe-574f-932f-8416ae85654e
DOI: 10.1016/j.annonc.2024.08.692

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplificationsDOI 10.1016/j.annonc.2024.08.692Read

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.Semantic proximity Read

Precision Targeting of Mutant PI3Kα.Semantic proximity Read

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.Semantic proximity Read

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Semantic proximity Read

Targeting the PI3K-Akt pathway in human cancerSemantic proximity Read

663P First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumorsSemantic proximity Read

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers.Semantic proximity Read

Somatic mutations in PI3Kα: Structural basis for enzyme activation and drug designSemantic proximity Read

A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progressionSemantic proximity Read

Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent InhibitorsSemantic proximity Read

Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.Semantic proximity Read

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesSemantic proximity Read